European Academy of Neurology (EAN) Congress 2024

A study presented at EAN 2024 found that selective exposure to parental smoking at an early age may increase the risk of developing multiple sclerosis (MS) later in life.

Having frequent distressing dreams may signal a higher risk of developing cognitive decline and dementia in adults, according to a prospective study of three population-based cohorts.

Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.

Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.